QOP
SMMT icon

Quinn Opportunity Partners’s Summit Therapeutics SMMT Stock Holding History

Quinn Opportunity Partners’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,000
Closed -$85.8K – 306
2024
Q2 		$85.8K Buy
+11,000
New +$59.4K 0.01% 257

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Quinn Opportunity Partners's SMMT Position: Q3 2024 in Review

Quinn Opportunity Partners sold out of Summit Therapeutics (SMMT) in Q3 2024, closing a stake of 11,000 shares — an estimated $85.8K sold.

Quinn Opportunity Partners first reported a position in SMMT in Q2 2024 and held it in 1 quarter. The position peaked at $85.8K in Q2 2024. 166 funds tracked by Wall St. Rank hold SMMT as of Q3 2024.

  • Quinn Opportunity Partners reported no remaining Summit Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Quinn Opportunity Partners sold 11,000 Summit Therapeutics shares in Q3 2024, an estimated $85.8K.
  • Quinn Opportunity Partners first reported a position in Summit Therapeutics in Q2 2024 and held it in 1 quarter.
  • Quinn Opportunity Partners's Summit Therapeutics position peaked at $85.8K in Q2 2024.
  • 166 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2024.

Based on Quinn Opportunity Partners's 13F filing for Q3 2024, filed 13 Nov 2024.